Claritev (NYSE:CTEV) EVP Buys $247,500.00 in Stock

Claritev (NYSE:CTEV) EVP Michael Kim purchased 15,000 shares of the business’s stock in a transaction on Thursday, March 12th. The stock was purchased at an average price of $16.50 per share, for a total transaction of $247,500.00. Following the acquisition, the executive vice president owned 182,878 shares of the company’s stock, valued at approximately $3,017,487. This represents a 8.94% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Michael Kim also recently made the following trade(s):

• On Friday, February 27th, Michael Kim acquired 30,000 shares of Claritev stock. The shares were purchased at an average price of $14.30 per share, with a total value of $429,000.00.

Claritev Price Performance

Shares of NYSE:CTEV traded up $1.64 during trading on Monday, reaching $18.53. 21,815 shares of the stock were exchanged, compared to its average volume of 226,946. Claritev has a 1-year low of $12.04 and a 1-year high of $74.07. The stock has a fifty day moving average of $23.93 and a two-hundred day moving average of $42.93. The firm has a market cap of $305.93 million, a price-to-earnings ratio of -1.07 and a beta of 0.61.

Hedge Funds Weigh In On Claritev

Several hedge funds have recently modified their holdings of the company. Invesco Ltd. boosted its stake in shares of Claritev by 4.8% in the 4th quarter. Invesco Ltd. now owns 22,802 shares of the company’s stock worth $975,000 after buying an additional 1,044 shares during the last quarter. FAS Wealth Partners Inc. increased its position in shares of Claritev by 20.5% during the fourth quarter. FAS Wealth Partners Inc. now owns 31,097 shares of the company’s stock valued at $1,329,000 after acquiring an additional 5,290 shares during the last quarter. XTX Topco Ltd bought a new stake in Claritev during the fourth quarter worth $729,000. Arini Captial Management Ltd bought a new stake in Claritev during the fourth quarter worth $64,291,000. Finally, Third Point LLC purchased a new position in Claritev in the fourth quarter worth $6,199,000. Institutional investors own 87.15% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CTEV. Citigroup decreased their target price on shares of Claritev from $63.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. Wells Fargo & Company set a $30.00 price target on Claritev and gave the company an “equal weight” rating in a research note on Tuesday, February 24th. Guggenheim reissued a “buy” rating on shares of Claritev in a report on Tuesday, February 24th. UBS Group restated a “buy” rating on shares of Claritev in a report on Tuesday, February 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Claritev in a research report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Claritev presently has an average rating of “Hold” and a consensus price target of $29.67.

About Claritev

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.